Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Windward Bio

Request full access

Ultra-long-acting antibodies for respiratory and skin diseases

Basel, SwitzerlandFounded 2024Biotech & Life Sciences

About Windward Bio

Windward Bio is a clinical-stage biotechnology company based in Basel, Switzerland, developing ultra-long-acting antibody medicines for people with serious respiratory and dermatologic immunological diseases. Its approach is to in-license clinical-stage antibodies against validated targets and extend their dosing intervals, aiming to cut the treatment burden of frequent injections in chronic conditions such as asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis. The lead candidate, WIN378, is a long-acting anti-TSLP monoclonal antibody licensed from Kelun-Biotech and Harbour BioMed; it is being evaluated with twice-yearly dosing in the Phase 2/3 POLARIS programme in asthma, with COPD as a further indication. The second programme, WIN027, licensed from Qyuns Therapeutics, is a long-acting bispecific antibody that blocks both TSLP and IL-13 and is being developed for respiratory and dermatology indications. Windward Bio's common shares trade on the Nasdaq Global Select Market under the symbol WWB.

Source: Dealroom company data

At a glance

Status
Operational
Employees
11
Open positions
1
Dealroom signal
95.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Immune System, Rumoured $1B, Biotech and Pharma, Rare Diseases, DT and LS, science-based, Swiss DT Biotech
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing May 2026 $165M $660M Sanofi · SR One · RTW Investments · RA Capital Management ↗
SERIES AOther financing Jan 2025 $200M $800M Omega Funds · RTW Investments · Quan Capital · Pivotal BioVenture Partners ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Windward Bio website traffic

Latest recorded traffic for Windward Bio is 2.5K monthly website visits, up 25% over the last three months. Windward Bio's team grew 0% over the past year.

Latest monthly visits2.5K 3-month web change+25% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Windward Bio in the Basel ecosystem

Live from Dealroom

The Windward Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

Series B and later4 investors entered at this stage

Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Windward Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.